Display Settings:

Format

Send to:

Choose Destination

    J Cancer Res Clin Oncol. 2008 Aug;134(8):833-9. Epub 2008 Feb 9.

    Antineoplastic effect of rapamycin is potentiated by inhibition of IRS-1 signaling in prostate cancer cells xenografts.

    Oliveira JC, Souza KK, Dias MM, Faria MC, Ropelle ER, Flores MB, Ueno M, Velloso LA, Saad ST, Saad MJ, Carvalheira JB.

    Departament of Internal Medicine, FCM-UNICAMP, Cidade Universitária Zeferino Vaz, Campinas, SP, 13081-970, Brazil.

    Proper activation of phosphoinositide 3-kinase-Akt pathway is critical for the prevention of tumorigenesis. Recent data have characterized a negative feedback loop, wherein mammalian target of rapamycin (mTOR) blocks additional activation of the Akt/mTOR pathway through inhibition insulin receptor substrate 1 (IRS-1) function. However, the potential of IRS-1 inhibition during rapamycin treatment has not been examined. Herein, we show that IRS-1 antisense oligonucleotide and rapamycin synergistically antagonize the activation of mTOR in vivo and induced tumor suppression, through inhibition of proliferation and induction of apoptosis, in prostate cancer cell xenografts. These data demonstrate that the addition of agents that blocks IRS-1 potentiate the effect of mTOR inhibition in the growth of prostate cancer cell xenografts.

    PMID: 18264722 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Click here to read

    Patient drug information

    • Sirolimus (Rapamune®)

      Sirolimus is used in combination with other medications to prevent rejection of kidney transplants. Sirolimus is in a class of medications called immunosuppressants. It works by suppressing the body's immune system.